|
|
Article: FDA Approves Pegasys(R) (peginterferon alfa-2a) in Combination with Copegus(TM) (ribavirin) for the Treatment of Hepatitis C; New Treatment Offers Dosing Regimen Based on Hepatitis C Virus Strain.
- Article from:
- PR Newswire
- Article date:
- December 4, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NUTLEY, N.J. -- Roche announced today that the U.S. Food and Drug Administration (FDA) has approved combination therapy with Pegasys(R) (peginterferon alfa-2a), a pegylated interferon, and Copegus(TM) (ribavirin) for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).
Pegasys and Copegus combination therapy was granted priority review designation by the FDA. Pegasys was approved as monotherapy for the treatment of adults ...